Navigation Links
Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
Date:9/11/2007

Generic Erosion of Zocor and Lipitor Will Cause Market Share of Statins to Drop Nearly 40% by 2016, According to a New Report from Decision Resources

WALTHAM, Mass., Sept. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market entry of novel angiogenic agents, including a future blockbuster drug from Genzyme, could revolutionize symptomatic treatment of peripheral arterial disease (PAD).

The new Pharmacor report Peripheral Arterial Disease finds that Genzyme's HIF-1 alpha therapy for PAD patients with intermittent claudication, which could reach the market as early as 2010, will garner sales of $1.5 billion in 2016 in the world's major pharmaceutical markets. Experts are optimistic about the market entry of novel angiogenic therapies, which act by generating new blood vessels in the legs and are the first agents to be developed as disease- modifying therapies for PAD. Although numerous studies will be required to establish the efficacy and safety of angiogenic products, physicians are hopeful these pioneering, PAD-specific therapies will be effective in treating the intermittent claudication and critical limb ischemia patient segments.

The report also finds that although statins will continue to dominate the PAD prescription landscape, the U.S. patent expiries of Merck's Zocor in 2006 and Pfizer's Lipitor in 2010 will cause total statin market share to drop from 58% in 2006 to 21% in 2016. The U.S. patent expiry of Zocor will prompt a rapid and extensive shift in prescribing to generic equivalents from 2007 onward as third-party payers remove the brand from formularies.

"Patient-share growth will be fastest for generic Zocor, which will overtake Lipitor for prescriptions in the majority of newly diagnosed PAD patients who may be unable to afford the high co-payments associated with Lipitor," said Mary Argent-Katwala, Ph.D., analyst at Decision Resources. "The decline in statin market share will then accelerate from 2011 to 2016 after the widespread patent expiry of Lipitor."

To listen to an interview with Dr. Argent-Katwala regarding the peripheral arterial disease drug market, please visit the Find Out More section of the Decision Resources home page on September 24, 2007, at http://www.DecisionResources.com.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase
2. High-Fidelity PCR with a Novel Polymerase Mixture
3. Challenge the Performance of Your Hot-Start PCRs with FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System
4. Combine High Yield, Great Accuracy and the Prevention of Carry-over Contamination by Using the Novel Expand High FidelityPLUS PCR System
5. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
6. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
7. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
8. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
9. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Life-sciences conference to feature novel research with clinical potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics (AMA), ... maker of unmanned aircraft systems (UAS), are launching a joint program to promote ... and support educational outreach efforts. , AMA and DJI will collaborate on other ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, 2017 ... on venture growth investments in biotechnology and medical ... Richardson , M.D. to Managing Director. ... He is a board observer at InfaCare Pharmaceutical ... investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence Pharmaceuticals ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today the ... Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial ... physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative ...
Breaking Biology Technology:
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
(Date:1/18/2017)... Jan. 18, 2017  In vitro diagnostic (IVD) companies ... and acquisitions (M&A), and Kalorama Information expects that trend ... have been shifting. Generally, uncertainty in reimbursement and healthcare ... U.S. has changed the acquisitions landscape. Instead of looking ... companies buying partners outside of their home country and ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
Breaking Biology News(10 mins):